Peripartum Cardiomyopathy and Sudden Cardiac Arrest: A Guide for OB/GYN and Cardiology Teams

Among the most emotionally complex challenges in cardiac care is the rare but devastating intersection of pregnancy, new motherhood, and sudden heart failure. Peripartum cardiomyopathy is a condition that arrives without warning, often striking young women who had no prior cardiac history at the most vulnerable moment of their lives. Understanding this condition – and the window of sudden cardiac arrest risk it creates – is essential for any clinician caring for pregnant or recently delivered patients.

What Is Peripartum Cardiomyopathy?

Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy with new-onset heart failure occurring in the last month of pregnancy or within five months after delivery, in the absence of another identifiable cause. The left ventricle dilates and the ejection fraction falls, often precipitously, in a patient who may have had completely normal cardiac function just weeks earlier.

The incidence of PPCM in the United States is approximately 1 in 1,000 to 1 in 4,000 deliveries, though the rate appears to be rising – possibly reflecting improved recognition, changing risk factor profiles, and shifting demographics in maternal age and underlying health. Black women are disproportionately affected, with incidence rates two to three times higher than in white women, and tend to present with more severe initial dysfunction and lower rates of full recovery.

Risk factors for PPCM include advanced maternal age, multiple gestation, hypertensive disorders of pregnancy, preeclampsia, prolonged tocolysis with beta-agonists, and prior PPCM. However, the condition occurs across all risk profiles – and its onset in women with no apparent risk factors is one of its most challenging features for both patients and the clinical teams caring for them.

PPCM is projected to account for nearly 40–48% of the wearable cardioverter defibrillator market by 2035, reflecting growing clinical recognition of the SCA risk this condition creates during the recovery window.

The Sudden Cardiac Arrest Risk in PPCM

The clinical course of PPCM varies widely, but a significant proportion of patients experience profound systolic dysfunction – LVEF below 35% – at presentation. This degree of dysfunction creates the same arrhythmic substrate that drives sudden cardiac death risk in any dilated cardiomyopathy: ventricular remodeling, myocardial fibrosis, and disrupted electrical conduction pathways that predispose to ventricular tachycardia and ventricular fibrillation.

The timing of PPCM’s presentation – during late pregnancy or the immediate postpartum period – creates an unusual clinical challenge for sudden cardiac arrest risk management. Many of the standard approaches to arrhythmic risk reduction are complicated or contraindicated in this patient population:

• ICD implantation  carries surgical risk that is particularly significant in a patient who may be delivering or who has just delivered, and may be unnecessary if LVEF recovers – which it does in the majority of PPCM patients given time and appropriate medical therapy.
• Guideline-directed medical therapy  including ACE inhibitors, ARBs, and certain beta-blockers, requires careful modification during pregnancy and breastfeeding, meaning the medical foundation of arrhythmic risk reduction is more complex than in non-obstetric patients.
• The patient is typically young,  active, caring for a newborn, and not inclined to restrict her activity – yet she is at meaningful risk of a life-threatening arrhythmia during physical exertion, emotional stress, or the fluid shifts of the early postpartum period.

Published data documents appropriate ventricular arrhythmia events in PPCM patients, including ventricular fibrillation and sustained VT requiring defibrillation, in the acute phase of the illness. The combination of low LVEF, the physiologic stress of the peripartum period, and the patient’s typically young age and high activity level creates a meaningful window of SCA risk that demands a protection strategy.

The LVEF Recovery Window: How Long Does Protection Need to Last?

One of the most distinctive features of PPCM, compared to other forms of cardiomyopathy, is the relatively high rate of spontaneous LVEF recovery. Studies suggest that 50–70% of PPCM patients recover LVEF to above 50% within 6–12 months of diagnosis when treated with optimal guideline-directed medical therapy. This recovery potential profoundly shapes the risk-benefit calculation for invasive device therapy.

The challenge is that recovery is neither universal nor predictable at the time of initial presentation. The patient whose LVEF is 20% at diagnosis has roughly even odds of substantial recovery and residual dysfunction. Implanting an ICD in a patient who will recover fully exposes her to unnecessary procedural risk, device complications, and the psychological burden of carrying a permanent implant. Deferring device therapy in a patient who will not recover exposes her to unprotected SCA risk during the waiting period.

The wearable cardioverter defibrillator elegantly resolves this dilemma. It provides the arrhythmic protection of an ICD – continuous monitoring and automatic defibrillation – without the surgical risk, irreversibility, or permanence of an implanted device. It can be worn for the duration of the recovery assessment window and then discontinued when LVEF recovers, or transitioned to ICD evaluation if it does not.

The Coordinated OB-Cardiology Care Model

PPCM sits at the interface of two clinical worlds that do not always communicate naturally: obstetrics and cardiology. Creating a coordinated care model between these specialties is one of the most impactful structural interventions available for this patient population. Key elements of a high-functioning OB-cardiology partnership include:

• Early recognition and referral:  OB/GYN teams and midwives should have a low threshold for cardiac evaluation when postpartum patients present with dyspnea, edema, fatigue, or reduced exercise tolerance beyond the first two weeks after delivery. These symptoms are common in normal postpartum recovery – which makes PPCM uniquely easy to miss.
• Immediate LVEF assessment:  Echocardiography should be performed promptly in any postpartum patient with new heart failure symptoms. The diagnosis of PPCM requires active exclusion of other causes, which echocardiography helps accomplish.
• Shared risk discussion:  The arrhythmic risk and the WCD option should be discussed with the patient and her family as part of the initial management conversation – ideally with a cardiologist present, but initiated by whichever clinician makes the initial diagnosis.
• Breastfeeding and medication counseling:  Many PPCM medications are compatible with breastfeeding; some are not. A collaborative approach to optimizing heart failure therapy while supporting the patient’s breastfeeding goals requires coordination between OB and cardiac pharmacology.
• Defined reassessment timeline:  Unlike cardiomyopathy in older adults, PPCM patients benefit from early, frequent LVEF reassessment – at 1–3 months, 6 months, and 12 months. Early signs of recovery can support appropriate de-escalation of device therapy.

Unique Compliance Considerations for New Mothers

Asking a woman who has just delivered a baby to wear a medical garment 23+ hours a day presents challenges that are distinct from other WCD patient populations. The clinical team should anticipate these and have practical responses ready:

• Sleep disruption:  New mothers sleep in fragmented cycles and in multiple positions. The WCD garment must be genuinely comfortable for sleep, including side-lying positions, to achieve consistent overnight wear.
• Newborn care activities:  Feeding, bathing, and lifting a newborn should all be possible while wearing a WCD. The garment should not restrict upper body movement or create pressure points that interfere with breastfeeding.
• Body image and emotional adjustment:  The postpartum period already involves profound physical and emotional adjustment. Framing the WCD as a temporary, protective measure – a companion for recovery, not a permanent limitation – is important for patient acceptance.
• Partner and family support:  Enlisting the patient’s partner, mother, or support network in understanding the WCD and its importance dramatically improves consistent wear. These individuals are present during the hours when clinical staff are not.

The ASSURE® Cardiac Recovery System: Built for This Moment

The ASSURE® Wearable Cardioverter Defibrillator from Kestra Medical Technologies was designed with patient comfort at its core – and for PPCM patients navigating the extraordinary demands of new motherhood alongside a cardiac diagnosis, that design philosophy matters deeply.

The ASSURE SensorFit Garment is available in female-specific fits, using breathable, lightweight fabric with non-adhesive, cushioned ECG sensors that move with the body. The design supports the active, sleep-fragmented, physically demanding life of a new mother while maintaining the 24/7 cardiac monitoring and automatic defibrillation capability that her clinical situation demands.

In the ACE-PAS real-world study of 5,929 ASSURE patients, the system achieved a median daily wear time of more than 23 hours – a result that reflects how well patients tolerate the system when garment design prioritizes the lived experience of wearing a medical device. For a new mother being asked to add one more thing to her already extraordinary daily demands, the difference between a comfortable garment and an uncomfortable one is the difference between consistent protection and inadequate protection.

The Kestra CareStation™ platform gives the coordinating cardiology team continuous remote visibility into PPCM patient wear time, arrhythmia events, and compliance trends – enabling proactive outreach when the data suggests a patient is struggling, without requiring an additional office visit during what is already an overwhelming time. For this uniquely vulnerable population, the ASSURE system provides the protection that fills the gap between diagnosis and the recovery that, for most PPCM patients, is genuinely within reach.

© Kestra Medical Technologies, Ltd.  ·  kestramedical.com  ·  For informational purposes. Not a substitute for professional medical advice.